Series Seed Round
Join LumenGuides in advancing interventional pulmonology through autonomous robotic navigation, intraluminal optical sensing, and AI-driven airway reconstruction
The Challenge
A persistent gap in lung cancer diagnosis
Our Solution
Naviscope — Autonomous Bronchoscopic Navigation Platform
Key Technical & Clinical Differentiators
Technology designed to advance bronchoscopic navigation
Progress & Validation
Key milestones achieved
Market Opportunity
Addressing a significant unmet need
Funding Status
LumenGuides has secured $2.8M to date and was recently awarded the maximum grant under the Israel Innovation Authority (IIA) Seed Program (6M NIS). Under the grant terms, release of the IIA funding is contingent upon completion of a matching private investment, which must be deposited to unlock the grant. Accordingly, closing the matching round by early March is a critical milestone.
Use of Funds – $1.5M Seed Round
Clinical Development
40%30-patient First-in-Human pilot study
Regulatory Pathway
25%FDA 510(k) preparation and submission
Product Development
25%Design optimization and manufacturing scale-up
Team Expansion
10%Key clinical, regulatory, and engineering hires
18-Month Milestones
Our Team
Leadership
Limor Prigan
CEO
Former leadership roles at Fujifilm, Avertto Medical, Kornit Digital
Yaniv Kirma
CTO
Co-founder of Fibernova (acquired by Broncus Medical)
Prof. Doron Kopelman
CMO
Former Head of Surgery, Technion; President, Israeli Surgical Association
Dan Vigdor
Global Business Development (USA)
International commercialization and market-entry expert
Medical Advisory Board
- Prof. Eli Atar
- Prof. Moti Kramer
- Prof. Doron Kopelman
Why It Matters
By integrating robotics, intraluminal optical sensing, and AI, Naviscope represents a foundational step toward radiation-free, autonomous navigation in interventional pulmonology—with the potential to enable earlier lung cancer detection, reduce invasive procedures, and improve patient outcomes.